Compare Howmet Aerospace Inc (HWM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Howmet Aerospace Inc trades at $217.44 (market cap $86.48B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Howmet Aerospace Inc is far larger — about 88.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Howmet Aerospace Inc pays a 0.26% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HWM | MRVI | |
|---|---|---|
Market Cap | $86.48B | $972.90M |
Volume | 3,558,498 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $292.65 | $9.00 |
52-Week Low | $189.68 | $2.83 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $90.58B | $1.08B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $216.84, down 1.8% with bearish technical signals despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.33 exceeding expectations. Revenue growth continues with 2026 projections showing $9.1B revenue and 20.52% net margin. Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 51% upside potential.
The stock presents compelling growth potential driven by aerospace demand and defense modernization trends, though technical weakness and valuation concerns at 46.7x P/E warrant caution. Strong cash flow generation supports shareholder returns including dividends and buybacks, while supply chain risks and competitive pressures remain key watchpoints for investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
